Announcements Trials
Browse Landscape

Phase

Phase 3 4Phase NA 3Phase 4 2Phase EARLY_PHASE1 1Phase 2/3 1Phase 2 1

Status

Recruiting 1Enrolling by invitation 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Endocrine 1

Conditions

Prolactinoma 1Prolactin Deficiency, Isolated 1Pituitary Neoplasms 1Hyperprolactinemia 1

Interventions

Dexamethasone 49Metformin 47Cyclophosphamide 42Saline Solution 38Cytarabine 34Sodium Chloride 32Bupivacaine 31Vincristine 27Cisplatin 26Propofol 25Methotrexate 25Letrozole 24Fluorouracil 24Dexmedetomidine 24Doxorubicin 23Fentanyl 22Carboplatin 22Etoposide 19Rituximab 18Morphine 18Bevacizumab 18Acetaminophen 18Lidocaine 17Granulocyte Colony-Stimulating Factor 17Prednisone 16Mercaptopurine 16Docetaxel 16Clomiphene 16Sevoflurane 15Ropivacaine 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 4 × OTHER × Cabergoline × Clear all
NCT07045935 2025-09-23

ProBOLIC

University Hospital, Basel, Switzerland

Phase 4 Recruiting
60 enrolled

Prolactin Deficiency, Isolated, Hyperprolactinemia, Prolactinoma

NCT07034859 2025-06-24

Cabergoline in the Management of Nonfunctioning Pituitary Adenoma

National Taiwan University Hospital

Phase 4 Enrolling by invitation
30 enrolled
Endocrine

Pituitary Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡